Phase 2 N=87 A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Incidence of CMV Disease or CMV Viremia — 29; 9; 26 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=36 Utilization of Hepatitis C Positive Kidneys in Negative Recipients
Kidney Transplant · Hepatitis C · HCV
Primary: Proportion of Patients With Undetectable Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR) at 12 Weeks After Completion of HCV Treatment — 28 Participants
Phase 2 N=137 ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Transplantation Infection · Epstein-Barr Virus Infections · Cytomegalovirus Infections
Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants
Phase 2 N=83 A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
Cytomegalovirus (CMV) Infection · Kidney Transplantation
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 6; 3; 23; 12 Participants
Phase 4 N=40 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
Phase 4 N=10 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants
Phase 4 N=10 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
N/A N=14 An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients
Cytomegalovirus Infections
Primary: Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis — 3 participants
Phase 2 N=62 Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients
End Stage Renal Disease
Primary: Number of Subjects Cured — 62 Participants
Phase 2 N=150 A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Primary: Percentage of Participants With CMV Viremia Through 1 Year Post First Study Drug Injection — 35.6; 35.6; 5.5; 0 Percentage of Paticipants — p=0.307
Phase 2 N=17 Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
EBV Viremia · CMV Viremia
Primary: Incidence of EBV or CMV Related Disease in Transplant Recipient — 2; 0 participants
Phase 3 N=326 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Cytomegalovirus Infections
Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002
Phase 3 N=299 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Cytomegalovirus Infections
Primary: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months — 14.1; 42.6 percentage of participants
Phase 2 N=58 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Cytomegalovirus
Primary: Number of Participants With a Complete Response — 8; 50 Participants
Phase 4 N=70 Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
Transplant Complication · CMV
Primary: Clinical Significant Leukopenia — 8; 1 Participants
Phase 2 N=20 Role of Everolimus in Highly Sensitized Patients
Highly-sensitized Kidney Transplant Recipients
Primary: The Number of Polyoma BK Viremia Patients — 5 Participants
Phase 2 N=527 Calcineurin Inhibitor Sparing After Kidney Transplantation
CNI Side Effects
Primary: Phase I: The Minimization of Negative Side Effects - Patient Survival — 99; 98 percentage of participants
Phase 2 N=26 Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Phase 4 N=1,209 Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
Kidney Transplant Infection
Primary: Incidence of Cytomegalovirus Infection or Disease — 9; 7; 39 Participants
Phase 3 N=32 Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Transplant; Failure, Kidney
Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32
N/A N=800 A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
Cytomegalovirus (CMV) Infections Among Children and Adult Liver Transplantation Patients in China
Primary: Number of Participants With Clinically Significant CMV Reactivation or CMV Disease — 62; 89; 78; 32 Participants
Phase 3 N=22 MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
Cytomegalovirus Infection · Cytomegalovirus Disease
Primary: Percentage of Participants With Adverse Events (AEs) — 90.9 Percentage of Participants
Phase 4 N=236 Letermovir Use in Heart Transplant Recipients
Cytomegalovirus Disease · Cytomegalovirus Infections · Heart Transplant Infection
Primary: Proportion of Patients With Neutropenia Compared to Historical Controls — 0; 30 Participants — p=0.02
Phase 2 N=1 Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
Leukemia · Lymphoma
Primary: Number of Participants With Non-Relapse Mortality — 0 Participants
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
N/A N=40 Using mTOR Inhibitors in the Prevention of BK Nephropathy
BK Viremia · BK Nephropathy
Primary: Number of Participants With BK Viral Load <600 Copies/mL — 13; 17 Participants
Phase 2 N=29 CMX001 in Post-transplant Patients With BK Virus Viruria
Viruria
Primary: Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria — 1; 1; 1; 2 Participants
N/A N=170 Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
Acute Graft Rejection · Chronic Allograft Nephropathy · Polyomavirus-related Transplant Nephropathy
Primary: Patient Survival — 96.4; 96.3 percentage of participants
Phase 4 N=57 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
Kidney Transplantation, Cytomegalovirus Infections
Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Withdrawal Due to AEs — 56; 41; 6 Participants
N/A N=878 Pre-engraftment Cytomegalovirus DNAemia
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days